Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate-chemotherapy

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 935-937

  Herbert, Kirsten E ^a   Ritchie, David S ^a,b   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

APHERESIS; CANCER COMBINATION CHEMOTHERAPY; DNA DAMAGE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 79957522124     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.575492     Document Type: Note

References (16)

1. Ritchie DS, Seymour JF, Grigg AP, et al. The Hyper-CVADrituximab chemotherapy program followed by high-dose busulphan, melphalan and autologous stemm cell transplantation produces excelleent event free survival in patients with previously untreated mantle cell lymphoma. Ann Haematol 2007;86:101-105. (Pubitemid 44964001)
2. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
3. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
4. Keane C, Gibbs S, Seymour JF, et al. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol 2006;24:159-163. (Pubitemid 44483910)
5. Hill BT, Rybicki L, Smith S, et al. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma 2011;52:986-993.
6. Sharp JG, Kessinger A, Mann S, et al. Outcome of highdose therapy and autologous transplantation in non- Hodgkins lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996;14:214-219.
7. Ho J, Yang L, Banihashemi B, et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkins lymphoma. Bone Marrow Transplant 2009;43:223-228.
8. Gill S, Lane SW, Crawford J, et al. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol 2008;87:727-734.
9. DiPersio J, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)G-CSF vs. GCSFplacebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007;110(Suppl. 1): Abstract 445.
10. DiPersio JF, Micallef IN, Stiff PJ, et al. , Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkins lymphoma. J Clin Oncol 2009;27: 4767-4773.
11. Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-69.
12. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34 cells from non-Hodgkins lymphoma, Hodgkins disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment:compassionate use data. Bone Marrow Transplant 2008;41:331-338. (Pubitemid 351330727)
13. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with GCSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009;43:909-917.
14. Kobold S, Isernhagen J, Hübel K, et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2010 Nov 22. [Epub ahead of print].
15. Duarte RF, Henao MG, dAddio A, et al. Predictability of stem cell mobilization following G-CSF plus/minus plerixafor based on day 4 peripheral blood CD34 levels: basis for a preemptive model of plerixafor use in patients with lymphoma and myeloma who mobilize poorly. Bone Marrow Transplant 2010;45(Suppl. 2): S323.
16. DAddio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356-363.